Claudia Haferlach

Claudia Haferlach's AcademicInfluence.com Rankings

Claudia Haferlach

Medical

#2831

World Rank

#3270

Historical Rank

Hematology

#41

World Rank

#47

Historical Rank

Oncology

#182

World Rank

#188

Historical Rank

medical Degrees

Claudia Haferlach

Philosophy

#8104

World Rank

#11424

Historical Rank

Logic

#5135

World Rank

#6506

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Claudia Haferlach Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Claudia Haferlach's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Frequent pathway mutations of splicing machinery in myelodysplasia (2011) (1799)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes (2013) (1219)
BRAF mutations in hairy-cell leukemia. (2011) (763)
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. (2009) (479)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) (2012) (401)
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. (2008) (383)
Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. (2014) (347)
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping (2007) (331)
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms (2012) (325)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. (2009) (321)
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. (2009) (319)
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. (2011) (315)
Dynamics of clonal evolution in myelodysplastic syndromes (2016) (311)
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. (2010) (299)
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). (2012) (285)
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes (2010) (280)
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (2014) (269)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. (2011) (262)
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. (2011) (259)
A novel hierarchical prognostic model of AML solely based on molecular mutations. (2012) (248)
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients (2014) (241)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype (2009) (236)
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. (2011) (232)
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. (2017) (226)
Landscape of TET2 mutations in acute myeloid leukemia (2012) (222)
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. (2016) (209)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. (2010) (208)
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype (2008) (203)
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome (2013) (197)
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. (2010) (195)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017) (189)
Monitoring of minimal residual disease in acute myeloid leukemia (2005) (187)
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. (2009) (170)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases (2011) (165)
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome (2014) (163)
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations (2013) (157)
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma (2007) (154)
The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL (2013) (150)
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases (2017) (146)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis (2016) (145)
The role of different genetic subtypes of CEBPA mutated AML (2014) (144)
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. (2007) (142)
Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML (2010) (141)
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance (2011) (141)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (2019) (141)
A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological Neoplasms (2009) (139)
Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo (2013) (126)
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status (2014) (121)
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q (2011) (121)
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia (2011) (119)
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. (2007) (119)
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. (2019) (119)
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study (2008) (118)
TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. (2014) (115)
High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome (2014) (109)
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). (2010) (106)
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. (2016) (103)
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG (2009) (99)
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease (2014) (99)
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features (2009) (91)
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis (2013) (90)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib (2014) (89)
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia (2014) (88)
The role of multiparameter flow cytometry for disease monitoring in AML. (2010) (85)
Eμ/miR-125b transgenic mice develop lethal B-cell malignancies (2011) (85)
Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups (2016) (84)
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma (2021) (84)
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. (2007) (84)
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia (2008) (83)
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. (2007) (82)
STAT3 mutations are highly specific for large granular lymphocytic leukemia (2013) (82)
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis (2010) (81)
Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data (2012) (81)
Landmark analysis of DNMT3A mutations in hematological malignancies (2013) (80)
Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype (2009) (80)
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis (2012) (80)
Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome (2010) (79)
Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes (2007) (78)
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies (2010) (78)
Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93% (2014) (76)
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. (2011) (76)
European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms (2019) (75)
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients (2013) (74)
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera (2009) (72)
Subtype-specific patterns of molecular mutations in acute myeloid leukemia (2017) (72)
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis (2009) (71)
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes (2015) (69)
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups (2014) (69)
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia (2011) (67)
AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions (2010) (67)
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. (2020) (66)
MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences (2018) (66)
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. (2012) (66)
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA (2011) (65)
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations (2015) (63)
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML (2015) (61)
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. (2011) (60)
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL). (2019) (60)
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms (2013) (60)
The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors (2007) (60)
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach (2007) (59)
Robustness of amplicon deep sequencing underlines its utility in clinical applications. (2013) (59)
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase (2013) (57)
Monoclonal B‐cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early‐stage CLL (2012) (57)
Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia (2010) (57)
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. (2012) (57)
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. (2020) (56)
CEBPA double‐mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis (2013) (56)
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics (2012) (56)
Genetic characterization of T‐PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker (2016) (56)
Application of an NGS‐based 28‐gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera (2016) (55)
Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations (2011) (55)
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters (2010) (53)
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. (2018) (53)
SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis (2013) (52)
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category (2009) (52)
Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients (2007) (51)
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. (2011) (51)
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group (2012) (50)
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers (2007) (50)
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events (2012) (50)
High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia (2013) (49)
A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (2018) (49)
Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome (2014) (49)
Integrated analysis of copy number alterations and gene expression: a bivariate assessment of equally directed abnormalities (2009) (49)
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells (2011) (48)
Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia (2012) (48)
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia (2014) (46)
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact (2014) (46)
An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling (2011) (46)
Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure (2011) (46)
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia (2016) (46)
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis (2010) (45)
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment (2015) (45)
IDH 1 mutations are detected in 6 . 6 % of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM 1 status (2010) (42)
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia (2016) (41)
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. (2006) (41)
Identification of a MYO18A‐PDGFRB fusion gene in an eosinophilia‐associated atypical myeloproliferative neoplasm with a t(5;17)(q33‐34;q11.2) (2009) (41)
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. (2010) (40)
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML (2011) (40)
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML (2007) (39)
Molecular diagnostics in acute leukemias (2009) (39)
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis (2018) (39)
Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis (2008) (39)
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 (2013) (38)
Clinical Utility of Multiparameter Flow Cytometry in the Diagnosis of 1013 Patients with Suspected Myelodysplastic Syndrome: Correlation to Cytomorphology, Cytogenetic, and Clinical Data. (2009) (38)
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements (2013) (37)
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia (2016) (36)
The role of the RAS pathway in iAMP21-ALL (2016) (36)
Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 (2018) (36)
Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms (2011) (35)
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase (2017) (34)
The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms (2018) (34)
Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study (2012) (34)
Correlation of flow cytometrically determined expression of ZAP‐70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia (2009) (33)
Insight into the molecular pathogenesis of myeloid malignancies (2007) (33)
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia (2018) (33)
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics (2013) (33)
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib (2008) (32)
Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV. (2009) (32)
Several lymphoma‐specific genetic events in parallel can be found in mature B‐cell neoplasms (2011) (32)
Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia (2018) (32)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes (2017) (32)
Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML (2018) (31)
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases (2012) (31)
Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment (2010) (31)
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes (2020) (31)
AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes (2009) (31)
Complex Landscape of Alternative Splicing in Myeloid Neoplasms (2020) (31)
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study (2020) (30)
Quantification of rare NPM1 mutation subtypes by digital PCR (2014) (30)
Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia (2015) (30)
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL (2019) (30)
Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms (2016) (30)
Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia‐associated myeloproliferative neoplasms (2015) (29)
Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. (2021) (29)
The new provisional WHO entity ‘RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia (2016) (28)
The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. (2010) (28)
JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases (2007) (28)
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML (2007) (28)
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases (2012) (27)
Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy (2007) (26)
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele (2012) (26)
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B‐cell neoplasms (2010) (26)
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow (2012) (26)
Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells (2011) (26)
AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients. (2015) (26)
Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene (2014) (25)
Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? (2012) (25)
High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (25)
Leukemia diagnosis: today and tomorrow (2015) (24)
Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases (2012) (24)
Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. (2012) (24)
MANGANESE deficiency. (2022) (24)
CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia (2011) (24)
Atypical mRNA fusions in PML‐RARA positive, RARA‐PML negative acute promyelocytic leukemia (2010) (23)
Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B‐CLL) and its genetic characterization (2014) (23)
Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. (2010) (23)
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase (2014) (23)
Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases (2013) (22)
Gene expression profiling in acute myeloid leukaemia (AML). (2009) (22)
Cytogenetic methods in chronic lymphocytic leukemia. (2011) (22)
Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing (2018) (22)
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q (2015) (22)
Identification and functional characterization of imatinib‐sensitive DTD1‐PDGFRB and CCDC88C‐PDGFRB fusion genes in eosinophilia‐associated myeloid/lymphoid neoplasms (2014) (21)
A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene (2013) (21)
The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time? (2020) (21)
How artificial intelligence might disrupt diagnostics in hematology in the near future (2021) (21)
BRCC3 mutations in myeloid neoplasms (2015) (21)
Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia. (2020) (21)
The European LeukemiaNet: achievements and perspectives (2011) (20)
Hematologist‐Level Classification of Mature B‐Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data (2020) (20)
Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients (2015) (20)
Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse (2017) (20)
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes (2021) (20)
Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms (2017) (20)
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes (2009) (19)
Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. (2012) (19)
Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia (2015) (19)
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies (2021) (19)
EZH2 mutations and their association with PICALM‐MLLT10 positive acute leukaemia (2012) (18)
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV (2018) (18)
The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia (2017) (18)
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration (2021) (18)
IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies (2018) (18)
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib (2007) (18)
Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients (2012) (18)
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy (2015) (17)
Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia (2012) (17)
Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients (2018) (17)
Male predominance in AML is associated with specific preleukemic mutations (2020) (16)
Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia (2019) (16)
Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia. (2021) (16)
BCR‐ABL1‐positive and JAK2 V617F‐positive clones in 23 patients with both aberrations reveal biologic and clinical importance (2017) (16)
Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity (2009) (16)
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS. (2020) (16)
Detection of centrosome aberrations in disease‐unrelated cells from patients with tumor treated with tyrosine kinase inhibitors (2010) (16)
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML (2021) (16)
Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions (2016) (15)
SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3 (2012) (15)
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia (2012) (15)
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML (2010) (15)
Interactive diagnostics in the indication to allogeneic SCT in AML (2009) (15)
Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN (2016) (15)
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. (2008) (15)
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma. (2010) (15)
The kinetics of relapse in DEK‐NUP214‐positive acute myeloid leukemia patients (2015) (15)
Gene expression profiling for the diagnosis of acute leukaemia (2006) (15)
Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups (2013) (15)
Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm—a comparison of 756 cases (2018) (15)
Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia (2016) (15)
Mixed Phenotype Acute Leukemia, T/Myeloid, NOS (MPAL-TM) Has a High DNMT3A Mutation Frequency and Carries Further Genetic Features of Both AML and T-ALL: Results of a Comprehensive Next-Generation Sequencing Study Analyzing 32 Genes (2012) (15)
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. (2013) (14)
Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia. (2007) (14)
Three Steps to the Diagnosis of Adult Ph-like ALL (2015) (14)
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. (2012) (14)
DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern (2019) (14)
Multiparameter flow cytometry reveals myelodysplasia‐related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms (2013) (13)
Involvement of the MLL gene in adult T‐lymphoblastic leukemia (2012) (13)
Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV (2011) (13)
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia (2016) (13)
MYC rearranged B-cell neoplasms: Impact of genetics on classification. (2016) (13)
Detection of Three Different MPLW515 Mutations in 10.1% of All JAK2 V617 Unmutated ET and 9.3% of All JAK2 V617F Unmutated OMF: A Study of 387 Patients. (2007) (12)
Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies. (2009) (12)
Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia (2015) (12)
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. (2021) (12)
Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V+ Advanced Systemic Mastocytosis (2015) (12)
A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence (2019) (12)
Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV (2008) (12)
The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers (2015) (11)
Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia (2016) (11)
Newly acquired kiwi fruit allergy after bone marrow transplantation from a kiwi‐allergic donor (2016) (11)
Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease (2018) (11)
A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls. (2011) (11)
Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. (2010) (11)
A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment (2008) (11)
Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics (2011) (11)
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia (2017) (11)
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative / myelodysplastic disorders : an analysis of 636 cases (2012) (10)
Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia. (2019) (10)
The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops (2021) (10)
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients (2021) (10)
Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1. (2014) (9)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV (2008) (9)
Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. (2010) (9)
Detailed molecular analysis and evaluation of prognosis in cases with high grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (2018) (9)
Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome (2013) (9)
Single and double hit events in genes encoding for immune targets before and after T cell engaging antibody therapy in MM. (2021) (9)
Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases. (2007) (8)
Analyses of 81 Chronic Myelomonocytic Leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 Revealed Mutations In 86.4% of All Patients with TET2 and EZH2 Being of High Prognostic Relevance (2010) (8)
TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes (2021) (8)
IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients (2009) (8)
Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. (2020) (8)
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. (2022) (8)
Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis (2016) (8)
Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations (2022) (8)
The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations (2016) (8)
ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome (2011) (8)
“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing? (2019) (8)
Prognostic Impact and Landscape of NOTCH 1 Mutations in Chronic Lymphocytic Leukemia ( CLL ) : a Study on 852 Patients Letter to the Editor Chronic lymphocytic leukemia (2013) (8)
Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype (2013) (8)
Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia (2021) (8)
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS . (2009) (8)
Discussion of the applicability of microarrays: profiling of leukemias. (2009) (7)
The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML). (2012) (7)
Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count (2020) (7)
Guidelines and Quality Assurance for Acquired Cytogenetics A common European framework for quality assessment for banded chromosome studies and molecular cytogenetic investigations of acquired abnormalities (2013) (7)
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes (2021) (7)
Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial. (2009) (7)
SRSF2 is Mutated in 47.2% (77/163) of Chronic Myelomonocytic Leukemia (CMML) and Prognostically Favorable in Cases with Concomitant RUNX1 mutations (2011) (7)
Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival (2019) (7)
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines (2018) (7)
Monitoring of Minimal Residual Disease Using Next-Generation Deep-Sequencing in 460 Acute Myeloid Leukemia Cases identifies RUNX1 Mutated Patients with Resistant Disease (2011) (6)
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (2021) (6)
SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients (2012) (6)
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk (2022) (6)
Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. (2013) (6)
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus (2016) (6)
Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg {+/-} IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV. (2010) (6)
Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia (2017) (6)
Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations (2019) (6)
In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML (2014) (6)
RQ‐PCR based WT1 expression in comparison to BCR‐ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib‐treated chronic myeloid leukaemia (2009) (6)
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia. (2007) (6)
Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing (2021) (6)
Screening for TP53 Mutations Identifies Chronic Lymphocytic Leukemia Patients with Rapid Disease Progression. (2007) (6)
European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms: reponse to the comments from the Francophone Group of Hematological Cytogenetics (GFCH) (2020) (6)
Cytogenetic Clonal Evolution in MDS Is Associated with Shifts towards Unfavorable Karyotypes According to IPSS and Shorter Overall Survival: A Study on 988 MDS Patients Studied Sequentially by Chromosome Banding Analysis (2011) (6)
STAT3 Mutations in Large Granular Lymphocytic Leukemia (2012) (6)
Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients (2010) (6)
Guidelines and Quality Assurance for Acquired Cytogenetics (2013) (6)
Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations (2016) (6)
Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia (2019) (6)
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). (2021) (5)
Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV. (2009) (5)
Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations (2015) (5)
Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes (2019) (5)
Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis (2016) (5)
A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1 (2013) (5)
[Diagnostics of acute leukemias: interaction of phenotypic and genetic methods]. (2012) (5)
The Role of Different Genetic Subtypes In CEBPA Mutated AML (2010) (5)
Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma (2019) (5)
Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA (2019) (5)
Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV (2012) (5)
Recurrent ATM and BIRC3 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) and Deletion 11q22-q23 (2012) (5)
Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms (2019) (5)
Evidence of clonality in cases of hypereosinophilia of undetermined significance (2019) (4)
RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome (2019) (4)
Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations with other biomarkers and clinical impact, a retrospective study on behalf of ERIC (2017) (4)
Older Age Is An Independent Risk Factor in AML (2008) (4)
Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases (2014) (4)
MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations (2016) (4)
RUNX1 Mutations in Normal Karyotype MDS Cooperate with Class I Mutations in the Progression to S-AML Following MDS. (2008) (4)
Genes break barrier between MDS and AML. (2015) (4)
leukemia lymphoid transformation in B-cell precursor acute lymphoblastic , is involved in CRLF2 Deregulated expression of cytokine receptor gene, (2011) (4)
PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2019) (4)
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis (2022) (4)
First Results of a 31-Gene Panel Targeted to Investigate Myeloid Malignancies by Next-Generation Amplicon Deep-Sequencing (2012) (4)
AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions. (2009) (4)
RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired (2008) (4)
A Novel Machine Learning Based in silico Pathogenicity Predictor for Missense Variants in a Hematological Setting (2019) (4)
The Potential of Molecular Genetic Analysis for Diagnostic and Prognostic Decision Making in Clonal Cytopenia of Undetermined Significance (CCUS) and MDS - a Study on 576 Patients (2020) (4)
The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia (2020) (4)
Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes (2019) (4)
An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma (2018) (4)
Impact of genetic alterations in stem-cell transplantation for myelodysplasia and secondary acute myeloid leukemia Short title: Genetic alterations in myelodysplasia with HCT (2017) (4)
Another piece of the AML puzzle. (2013) (4)
Correction to: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences (Leukemia, (2018), 32, 10, (2152-2166), 10.1038/s41375-018-0033-0) (2018) (4)
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics (2022) (4)
Molecular Analyses of MDS/MPN Overlap Entities According to WHO Classification Reveal a Distinct Molecular Pattern for MDS/MPN, Unclassifiable (2014) (4)
Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences (2018) (4)
CML Patients with Resistance to Tyrosine Kinase Inhibitors and without BCR-ABL1 Resistance Mutation Frequently Carry Other Gene Mutations (2014) (4)
Accumulation of Somatic Mutations As a Function of Aging: A Study on 4843 TET2 Mutated Patients in Comparison to Their Respective SNP Pattern (2015) (3)
“Clinical and Molecular Heterogeneity of Eosinophilia-Associated Myeloproliferative Neoplasms with a Translocation t(5;12)”. (2009) (3)
Mutational Screening Of CSF3R, ASXL1, SETBP1, and SRSF2 In Chronic Neutrophilic Leukemia (CNL), Atypical CML and CMML Cases (2013) (3)
Myelodysplastic Syndromes (MDS) With 20q Deletion Show a High Frequency Of Associated Cytogenetic and Molecular Lesions With An Association To U2AF1, SRSF2, and Prognostically Adverse ASXL1 Mutations (2013) (3)
Will a Peripheral Blood (PB) Sample Yield the Same Diagnostic and Prognostic Cytogenetic Data as the Concomitant Bone Marrow (BM) In Myelodysplasia? An International Study Comparing Cytogenetics and Interphase FISH Using Parallel PB and BM Samples (2010) (3)
Analysis of Mechanisms of Blast Crisis in Chronic Myeloid Leukemia By Whole Genome Sequencing (2020) (3)
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q (2022) (3)
Integrated Diagnostic Approach for Suspected Myelodysplastic Syndrome As a Basis for Advancement of Diagnostic Criteria (2016) (3)
Automated Peripheral Blood Cell Differentiation Using Artificial Intelligence - a Study with More Than 10,000 Routine Samples in a Specialized Leukemia Laboratory (2021) (3)
Prognostic Impact of FLT3 Mutation Load in NPM1 Mutated AML. (2009) (3)
Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients. (2016) (3)
Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML (2015) (3)
Abstract 5119: Frequent splicing pathway mutations and aberrant RNA splicing in myelodysplasia (2012) (3)
SOX11 over-Expression Is a Specific Marker for Mantle Cell Lymphoma and Correlates with t(11;14) Translocation, CCND1 Expression, and an Adverse Prognosis. (2012) (3)
Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox (2016) (3)
Categorizing Molecular Mutations in MDS and AML (2015) (3)
MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences. (2017) (3)
The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT (2020) (3)
Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses (2018) (3)
A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes (2020) (3)
Artificial Intelligence Substantially Supports Chromosome Banding Analysis Maintaining Its Strengths in Hematologic Diagnostics Even in the Era of Newer Technologies (2020) (3)
Machine Learning (ML) Can Successfully Support Microscopic Differential Counts of Peripheral Blood Smears in a High Throughput Hematology Laboratory (2020) (3)
The Validation of the BCR/ABL1-like Predictor across Laboratories Shows Reproducibility of Results (2019) (3)
Artificial intelligence in hematological diagnostics: Game changer or gadget? (2022) (3)
SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and ≥15% Ring Sideroblasts and Are Closely Related to FLT3-ITD and RUNX1 Mutations (2012) (3)
DNMT3A is a Powerful Follow-up Marker in NPM1 mutated AML (2014) (3)
Application of precision medicine in clinical routine in haematology—Challenges and opportunities (2022) (3)
Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma (2012) (3)
High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels (2019) (3)
Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia (2015) (3)
Molecularly Defined Clonal Evolution in Patients with Chronic Myeloid Leukemia Independent of the BCR-ABL Status (2014) (3)
Gene Amplifications Are Rare Events in AML and MDS and Are Associated with Complex Karyotype, TP53 Deletions and Very Poor Survival (2011) (3)
Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies (2013) (3)
Cooperating Molecular Mutations in AML1/RUNX1 Mutated AML Differ Dependent on the Cytogenetic Subgroup. (2007) (3)
Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML (2021) (3)
Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). (2009) (3)
An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data (2019) (3)
Genetic Patterns of Relapsed AML Differ Significantly from First Manifestation and Are Dependent on Cytogenetic Risk Groups at Diagnosis: Results in 175 Patients with Paired Samples (2014) (3)
Monoclonal B-Cell Lymphocytosis (MBL) Is Closely Related to Chronic Lymphocytic Leukemia (CLL) and May Be Better Classified as Early-Stage CLL. (2009) (3)
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV (2017) (2)
The TP53 Codon72 Polymorphism Is Associated with TP53 Mutations in Chronic Lymphocytic Leukemia (2011) (2)
Acute Lymphoblastic Leukemia (ALL) With Low-Hypodiploid/Near-Triploid Karyotype Is a Specific Clinical Entity Characterized By a High TP53 Mutation Frequency (2013) (2)
MMP (2020) (2)
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series (2022) (2)
9 or trisomy 9 (2011) (2)
Impact of 9q deletions on the classification of patients with acute myeloid leukemia (2019) (2)
Flow Cytometric Determination of ZAP-70 Expression by SBZAP Antibody: Impact of Type of Data Analysis on Correlation with IgVH Mutation Status, Cytogenetics, and Level of ZAP-70 mRNA Expression in 351 Patients with Chronic Lymphocytic Leukemia (CLL). (2007) (2)
Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes (2019) (2)
The Two Mutation Hot Spots Ser34 and Gln157 in U2AF1 Show Different Occurrence, Correlation and Clinical Features in Myeloid Malignancies: An Analysis of 785 Cases (2012) (2)
The RUNX1 Gene Is Altered in 26% of AML Patients Either By Translocation, Mutation, Gain or Deletion (2014) (2)
RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases (2013) (2)
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
Comprehensive Analysis of MYC Translocations in Multiple Myeloma By Whole Genome Sequencing and Whole Transcriptome Sequencing (2019) (2)
In CML Patients with Good Response to TKIs Other Gene Mutations Are Frequently (37%) Present in Addition to Philadelphia Negative, Cytogenetically Aberrant Clones but Are Rare (4%) in Cases with MMR and Normal Karyotype (2014) (2)
Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV. (2009) (2)
Genomic Complexity in Chronic Lymphocytic Leukemia Defined By Array-Based Analysis: Definitions, Associations with Other Biomarkers and Clinical Impact (2017) (2)
Prognosis of Mecom(EVI1)- rearranged MDS and AML Patients Strongly Depends on Accompanying Molecular Mutations but Not on Blast Counts (2015) (2)
Enhancer Hijacking of BCL11B Defines a Subtype of Lineage Ambiguous Acute Leukemia (2020) (2)
IDH Mutations Can Be Detected In 28.7% of All Normal Karyotype AML and Have Unfavourable Impact on the NPM1+/FLT3-ITD- Genotype (2010) (2)
MDS and AML With ≥15% Ring Sideroblasts Share Overlapping Features In Cytogenetics But Demonstrate Different Patterns and Incidences Of SF3B1 mutations (2013) (2)
Evaluation of the New Genetic Risk Classification of the European LeukemiaNet Recommendations in 1,110 Patients with De Novo AML and Proposal of a Refined Version (2011) (2)
Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. (2019) (2)
In Depth Characterization of CLL with Normal Karyotype By Array CGH and Mutation Screening (2015) (2)
Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS (2022) (2)
Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis (2016) (2)
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all demonstrating more than 50 % of bone marrow erythropoietic cells (2011) (2)
Translocations Involving the IGH@ locus Occur In 3.7% of Chronic Lymphocytic Leukemia and Are Associated with Unmutated IGHV Status and a Shorter Time to Treatment: A Study on 2,135 Cases (2010) (2)
Deep Learning Algorithms Support Distinction of PV, PMF, and ET Based on Clinical and Genetic Markers (2017) (2)
Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS (2019) (2)
Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy (2008) (2)
The gene expression classifier ALLCatchR identifies B-precursor ALL subtypes and underlying developmental trajectories across age (2023) (2)
Characterization of MDS Harboring TET2 Mutations and/or TET2 Deletions (2016) (2)
Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group (2011) (2)
Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma (2021) (2)
Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for the Genetic Characterization of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) in Adults (2021) (2)
Recurrent Mutations of the C-C Motif Chemokine Ligand 22 (CCL22) Define a Distinct Subgroup of Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK) (2020) (2)
Sole Trisomy 8 in AML: Concomitant Molecular Markers, Stability of Genetic Patterns and Impact On Outcome. (2012) (2)
Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3‐ITD to detect patients with prognostically adverse AML (2014) (2)
Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV. (2010) (2)
Cytogenetic and Molecular Genetic Characterization Of MLL-PTD Positive AML In Comparison To MLL-Translocated AML (2013) (2)
Major route additional chromosomal aberrations (ACA) precede increase of blasts in chronic myeloid leukemia (CML) independent of therapy. An analysis of CML studies III, IIIA and IV (2016) (2)
Development of An Oligonucleotide Resequencing Array for Rapid Mutation Analysis in Acute Myeloid Leukemia with Normal Karyotype. (2009) (2)
Somatic Mutations and Inborn Variants in Exon 12 of ASXL1 in Different Myeloid Neoplasms (2011) (2)
RUNX1 Mutations Reduce the Expression of CEBPA in Acute Myeloid Leukemia (2011) (2)
Detection of JAK2 Exon 12 Mutations in 10 Patients (10.1%) of V617F Negative PV: A Study of 211 Cases with PV or Suspected PV. (2007) (2)
Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype (2019) (2)
Cytogenetics of Chronic Myeloid Leukemia (CML) (2021) (2)
Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV (2012) (2)
A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next‐generation sequencing can be revealed by comparative bioinformatic analyses (2014) (2)
Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53 (2015) (2)
Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets (2019) (2)
AML with Inv(3)(q21q26) or t(3;3)(q21;q26) Are Frequently Accompanied by Mutations in RUNX1 and NRAS and Show a High Incidence of NF1 Deletions: a Study On 40 Cases. (2009) (2)
Comprehensive molecular characterization of myeloid malignancies with 9q deletion (2019) (2)
Diagnostic Value of CD200 Expression for the Differentiation Between Chronic Lymphocytic Leukemia (CLL), CLL with Increased Prolymphocytes (CLL/PL) and Mantle Cell Lymphoma. (2012) (2)
PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis (2019) (2)
Distinct, Ethnic, Clinical, and Genetic Characteristics of Myelodysplastic Syndromes with Der(1;7) (2019) (2)
Smoldering Development of Acute Megakaryoblastic Leukemia with Clonal Evolution in an Infant without Down Syndrome (2017) (1)
TP53 Mutations Are Present In 15.7% Of ALL, Are Especially Frequent In ALL With MYC-Rearrangement and In ALL With Low Hypodiploid Chromosome Status and Are Associated With Poor Prognosis (2013) (1)
Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1 (2012) (1)
Rising Percentages of Blasts Are Associated with Continuously Increasing Frequencies of FLT3 -ITD and NPM1 Mutations In AML and In Addition Depend on Combinations of These Markers: Analysis of 805 Cases with Normal Karyotype AML. (2010) (1)
An Accumulation of Cytogenetic and Molecular Genetic Events Characterizes the Progression From MDS to Secondary AML: An Analysis of Paired Samples in 38 Patients Analyzed by Cytogenetics, Mutation Analysis and SNP Microarrays. (2009) (1)
Specific Patterns of Molecular Mutations Determine the Morphologic Differentiation Stages in Acute Myeloid Leukemia (AML) (2014) (1)
Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement (2022) (1)
Cloning and characterization of a novel druggable fusion kinase in acute myeloid leukemia (2019) (1)
RUNX1 Deletions Are a Novel Mechanism of Loss of Function in AML and Are Associated with Adverse Cytogenetics. (2012) (1)
Mutations in CALR Are Associated with Del(13q) and Are Mutually Exclusive of Monosomy 7 in BCR-ABL1-Negative MPN (2014) (1)
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA (2017) (1)
Abstract 1514: Significance assessment of mutations in 944 MDS patients using publicly available variant databases and mutation impact prediction software (2016) (1)
Characterization and Quantification Of Rare BCR-ABL1 Fusion Transcripts (2013) (1)
FISH and WGS in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma - WGS Will Affect Future Treatment Decisions (2021) (1)
Mutational Patterns and Correlation to Chip-Related Mutations in Hematological Malignancies - a Study on Mutation Frequencies of 122 Genes in 28 Entities Including 3096 Cases (2020) (1)
The Number of RUNX1 Mutations and the Presence of One Intact RUNX1 Allele Influence Cytogenetic Abnormalities, Additional Molecular Mutations and Prognosis in RUNX1 Mutated AML (2016) (1)
Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations (2015) (1)
Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis (2019) (1)
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]. (2006) (1)
Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML (2010) (1)
Cytogenetic Aberrations In Lymphoplasmacytic Lymphoma (LPL): A Study On 166 Cases (2010) (1)
Flow Cytometric Identification of Biclonal Disease Among 5,523 Patients with Chronic Lymphocytic Leukemia and Its Genetic Characterization (2010) (1)
61 Clinical impact of multiparameter flow cytometry in diagnosing myelodysplastic syndromes (2011) (1)
A Specific Gene Expression Signature Affecting the Beta-Catenin and Notch Signaling Pathways and the Downregulation of MALAT1 Prove Acute Myeloid Leukemia with Limited Differentiation (AML-LD) as a Distinct Entity with NPM1 Mutation. (2009) (1)
A comprehensive approach to the diagnosis of MDS after triage by morphology towards cytogenetics and other techniques (2007) (1)
Impact of 9q Deletions on the Classification in AML (2017) (1)
Array CGH Identifies Copy Number Changes In 10% Of 520 MDS Patients With Normal Karyotype: Deletions Encompass The Genes TET2, DNMT3A, ETV6, NF1, RUNX1, and STAG2 and Are Associated With Shorter Survival (2013) (1)
Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment (2017) (1)
Flow Cytometric Findings Indicative of Myelodysplasia Differ Depending on the Karyotype (2008) (1)
How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study (2022) (1)
Correlation of CD30 Expression on Neoplastic Mast Cells in Systemic Mastocytosis Assessed By Immunohistochemistry Versus Multiparameter Flow Cytometry and Correlation to Clinical Parameters (2015) (1)
AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages? (2022) (1)
Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients (2022) (1)
Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation (2020) (1)
TP53 Mutations Are the Most Unfavorable Genetic Alteration in AML (2012) (1)
Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients (2010) (1)
C009 Identification of dysplastic features in patients with myelodysplastic syndromes by multiparameter flow cytometry and correlation with cytomorphology and cytogenetics (2007) (1)
Presentation and Diagnosis: Novel Molecular Markers and their Role in the Prognosis and Therapy of Acute Myeloid Leukemia (2011) (1)
In CLL with Normal Karyotype By Conventional and Genomic Array Karyotyping the Prognostic Impact of an Unmutated IGHV Status Is Stronger Than the Impact of Gene Mutations (2016) (1)
In Chronic Lymphocytic Leukemia the Gain of the Short Arm of Chromosome 2 Is Highly Associated with an Unmutated IGHV status, 11q/ATM Deletion, SF3B1 Mutation and a Complex Karyotype (2016) (1)
Equivalence of BCR-ABL Transcript Levels <1% According to the International Scale with Complete Cytogenetic Response in Chronic Phase CML Patients. (2012) (1)
Acquired Imatinib Resistance in CML Is Associated with TKD Mutations of the BCR-ABL Fusion Gene and/or Additional Chromosomal Aberrations: Certain TKD Mutations but Not TP53 Mutations Are Associated with Chromosome Instability. (2008) (1)
Single Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. (2022) (1)
Next-Generation Deep-Sequencing Enables a Quantitative Monitoring of RUNX1 Mutations in 534 Patients with Myelodysplastic/Myeloproliferative Neoplasms and Myelodysplastic Syndromes (2011) (1)
Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders (2020) (1)
The Biological and Clinical Implications of the Alternative Splicing Landscape of 1,258 Myeloid Neoplasm Cases (2019) (1)
Combined Impact of Aberrant Immunophenotypes, Somatic Mutations and Cytogenetic Aberrations on the Probability of Developing Myelodysplasia in Patients with Cytopenias of Undetermined Significance (2018) (1)
FISH Analysis In 843 Cases with Myeloid Malignancies Revealed TET2 deletions In 6% of Patients Which Were Accompanied by TET2 Mutations In 51% of Cases (2010) (1)
Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes (2013) (1)
Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients (2019) (1)
Comprehensive Analysis Of U2AF1 Mutations In 843 Patients With Myeloid Neoplasms With Respect To Other Genetic Alterations (2013) (1)
Whole Genome Sequencing Identifies Single Nucleotide Variants, Structural and Copy Number Abnormalities with a High Sensitivity in Hematological Neoplasm: An All in One Diagnostic Tool Tested on 3241 Cases (2018) (1)
Next-Generation Sequencing (NGS) in CMML, MDS and AML Detects Molecular Mutations in Oncogenes and Allows the Identification of Balanced Chromosomal Abnormalities with Extraordinary Sensitivity and Specificity. (2009) (1)
Machine Learning Algorithm Correctly Identifies 95% of Cells in Differential Count of Blood Smears: A Prospective Study on >29,000 Cases and >17 Million Single Cells (2022) (1)
Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) (2018) (1)
Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence (2020) (1)
Sequential Evolution Versus a Single Catastrophic Event (Chromothripsis) in the Pathogenesis of AML with Complex Aberrant Karyotype (2012) (1)
Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT (2009) (1)
Cyclin D1 ( CCND1 ) mRNA Expression Assessed by Real-Time PCR Is Increased in Patients with Mantle Cell Lymphoma and Contributes to Diagnosis in B-Cell Lymphoma Cases (2012) (1)
Molecular Screening In Blastic Plasmacytoid Dendritic Cell Neoplasms Reveals Mutations In TET2 and ASXL1 In The Majority Of Patients (2013) (1)
Targeted Next-Generation Sequencing and Genome-Wide High-Resolution Copy Number DNA Arrays Allow the Identification of Five Novel RUNX1 Fusions In Hematological Malignancies. (2010) (1)
Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q (2014) (1)
Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases (2022) (1)
Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with PM-Rara, CBFB-MYH11, and RUNX1-RUNX1T1: A Study on 600 Patients (2015) (1)
Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML. (2009) (1)
Prognostic relevance of FLT3-TED mutations in AML : the combination matters-an analysis of 3082 patients. Commentary (2008) (1)
Comparison of TP53 Alterations in Hematological Malignancies (2015) (1)
RUNX1 Mutations Play a Major Role in the Progression of MDS to S-AML Following MDS: A Genetic and Cytogenetic Analysis of Sequential Samples (2008) (1)
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q (2021) (1)
P735: THE ROLE OF SF3B1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES (2022) (1)
Myeloid Malignancies With Isochromosome 17q Harbor Frequently Mutations In ASXL1, SETBP1, and SRSF2 - This Distinct Genotype Presents With Various Morphological Phenotypes (2013) (1)
Multiparameter Flow Cytometry in Patients with Suspected Myelodysplastic Syndromes Adds Significant Prognostic Information: A Study on 1,013 Patients (2011) (1)
The Use of Unique Molecular Identifiers (UMIs) Strongly Improves Sequencing Detection Limits Allowing Earlier Detection of Small TP53 Mutated Clones in Leukemias (2016) (1)
Coexistence and Prognostic Significance of EVI1 Expression and Driver Mutations in KMT2A-Rearranged Acute Myeloid Leukemia (2019) (1)
Robust and Sensitive Detection of Insertions, Deletions and Point Mutations In CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing (NGS). (2010) (1)
The Outcome in AML Is Predicted by Cytogenetics, NPM1/FLT3 Mutation, Age and Sex, but Not by Treatment Variables. (2007) (1)
Landmark Analyses of DNMT3A Mutations in Hematological Malignancies (2011) (1)
TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype (2022) (1)
Sensitive Monitoring of Minimal Residual Disease Status in CEBPA-Mutated Acute Myeloid Leukemia Using Amplicon Deep-Sequencing (2011) (1)
Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling (2022) (1)
Myeloid Nuclear Differentiation Antigen (MNDA) Expression: A Useful Marker in the Diagnosis of Myelodysplastic Syndromes By Flow Cytometry (2015) (1)
Whole Genome Sequencing in Hairy Cell Leukemia-Variant (HCL-v) and Splenic Marginal Zone Lymphoma (SMZL) (2017) (1)
The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q (2018) (1)
Specific subtype distribution with impact on prognosis of TP53 single hit and double hit events in AML and MDS. (2023) (1)
A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics (2013) (1)
Targeted Next-Generation Sequencing (NGS) Enables a Broad Screening of 95 Molecular Mutations In a One-Step Approach and Detects Recurrent Mutations In AML with a Normal Karyotype In MYH11 and NOTCH1 (2010) (1)
CSF3R Mutations Are Predominantly Subclonal Events in Intermediate Risk Karyotype AML and Prevalently Occur with CEBPA Mutations (2016) (1)
Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms (2021) (1)
Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts (2022) (1)
Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups, (2011) (1)
Numerous Genomic Abnormalities in AML with Normal Karyotype. (2007) (1)
CDKN1B Encoding the Cyclin-Dependent Kinase Inhibitor 1B (p27) but Not ETV6 Is Located in the Minimally Deleted Region of 12p Abnormalities in Myeloid Malignancies and Its Expression Is Associated with Outcome in Acute Myeloid Leukemia (AML). (2009) (1)
Prospective Next-Generation Sequencing of Mutations in the ABL1 Kinase Domain in CML Patients Lacking Optimal Response According to ELN Guidelines (2016) (1)
WGS and RNA-Seq Is Superior to Conventional Diagnostic Tests in Multiple Myeloma: Ready for Prime Time? (2018) (1)
Deletion 7q Is Associated with KLF2 and NOTCH2 Mutations and Is Strongly Correlated with Splenic Marginal Zone Lymphoma but Also Found in Lymphoplasmacytic Lymphoma and Hairy Cell Leukemia Variant (2017) (1)
Further Insights Into The Molecular Landscape Of De Novo Acute Myeloid Leukemia (AML) Investigating 1,291 Patients (2013) (1)
Whole Genome Sequencing Identifies Microdeletions Affecting TET2 and RUNX1 with Clinical Impact in Myeloid Malignancies (2021) (1)
Gene expression analyses in acute myeloid leukaemia (AML): current status and perspectives (2008) (1)
Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV, (2011) (1)
Cytogenetic and Molecular Genetic Clonal Evolution in CLL Is Associated with an Unmutated IGHV Status and Frequently Leads to a Combination of Loss of 17p and TP53 mutation (2016) (1)
The Impact of Homozygosity and Size of the 13q Deletion in Patients with CLL (2012) (1)
Comparison of Mutation Patterns Between Diagnosis and Relapse in 444 Patients with Acute Myeloid Leukemia Shows High Variability of Stability and Influence On Time to Relapse (2012) (1)
Molecular Screening Applying a Pan-Myeloid Gene Panel Reveals Mutations in All Patients with Acute Undifferentiated Leukemia (2014) (1)
Assessment Of Human Equilibrative Nucleoside Transporter 1 (hENT1) – Expression By Flow Cytometry In Acute Myeloid Leukemia and Myelodysplastic Syndromes and Correlation To Clinical Outcome In Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy (2013) (1)
Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia (2021) (1)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies. (2009) (1)
17p Deletion Is the Most Frequent Abnormality Acquired During Clonal Evolution in Chronic Lymphocytic Leukemia (CLL): 429 Cases Analyzed by Interphase FISH and Chromosome Banding Analysis, (2011) (1)
Correlation of Mutation Patterns with Patient Age in 2656 Cases with 11 Different Hematological Malignancies (2020) (1)
Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS (2019) (1)
Patients with TP53 Disruption and IGHV Mutated Status Show Indolent Clinical Course: A Study on 1,327 Treatment-Naive CLL Cases (2016) (1)
Prognostic Value of “Monosomal Karyotype” in Comparison to “Complex Aberrant Karyotype” in AML: A Study on 824 Cases with Aberrant Karyotype (2011) (1)
T-Cell Acute Lymphoblastic Leukemia Can be Subdivided into Six Genetically Distinct Subtypes with Prognostic Impact By Combination of Whole Genome and Whole Transcriptome Data (2020) (1)
Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment (2015) (1)
Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations (2016) (1)
In CLL with Complex Aberrant Karyotype Distinct Entities Can Be Deciphered by Molecular Genetic and Cytogenetic Parameters (2008) (1)
Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia (2021) (1)
Does Age of Patients Influence the Composition of Gene Mutations in Myeloid Neoplasms (2015) (1)
Gene Amplifications In 84 Patients With Acute Myeloid Leukemia and 31 Patients With Myelodysplastic Syndrome Investigated By Array CGH (2013) (1)
Employment of Machine Learning Models Yields Highly Accurate Hematological Disease Prediction from Raw Flow Cytometry Matrix Data without the Need for Visualization or Human Intervention (2020) (1)
Comparative Assessment Of Minimal Residual Disease In Acute Myeloid Leukemia By Flow Cytometry and Molecular Genetics (2013) (1)
leukemia identifies heterogeneous secondary genomic alterations SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid (2011) (1)
A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker (2014) (1)
Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia (2019) (1)
A Comprehensive Deep-Sequencing Study of Blast Crisis Chronic Myeloid Leukemia (CML) Reveals New Insights Into Molecular Heterogeneity and Detects Mutations In 12 Different Genes In 82.5% of Cases (2010) (1)
SF3B1 Mutations in AML, MDS and MDS/MPN-RS-T Are Accompanied By Different Other Gene Mutations: Impact for Targeted Treatment Studies (2016) (1)
SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase (2022) (1)
Excess Coincidences of Hematopoietic Neoplasms (2015) (1)
Similar Patterns of Chromosome Abnormalities in CML Occur in Addition to the Philadelphia Translocation with or without Tyrosine Kinase Inhibitor Treatment. (2009) (0)
Use Of Flow Cytometry To Identify Myelodysplasia In Peripheral Blood (2013) (0)
Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression (2014) (0)
The Cytogenetic Profile In Lymphoid and Myeloid CML Blast Crisis (2013) (0)
The Impact Of Balanced and Unbalanced Karyotypes On Prognosis Of CML: From Chronic Phase To Blast Crisis (2013) (0)
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (2021) (0)
Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial (2011) (0)
P404: PROGNOSTIC IMPACT OF CEBPA-MUTATIONAL SUBGROUPS IN ADULT AML – RESULTS OF A LARGE METAANALYSIS IN MORE THAN 1000 CEBPA-MUTANT PATIENTS (2022) (0)
P624: CHROMOTHRIPSIS IN PATIENTS WITH CLL AND COMPLEX KARYOTYPE: PATTERNS OF ABERRATIONS AND PROGNOSTIC VALUE (2022) (0)
Landscape of TET2 Mutations In Acute Myeloid Leukemia (AML): A Next-Generation Sequencing Study Investigating 76 Cases Comprehensively Characterized for Cytogenetics and Other Molecular Markers. (2010) (0)
TP53 Mutations, Deletions, and CN-LOH: Comparison of TP53 single Hit and Double Hit Events and Their Impact on Prognosis in Hematological Malignancies (2021) (0)
Risk prediction in MDS: independent validation of the IPSS-M—ready for routine? (2023) (0)
Acute Myeloid Leukemia With t(8;21)/RUNX1-RUNX1T1 demonstrate a High Number Of Secondary Genetic Lesions: Frequency and Impact On Clinical Outcome (2013) (0)
Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia Characterization and Prognostic Relevance (2010) (0)
A Comprehensive Panel of Molecular Mutations Notably Improves a Cytogenetic Prognostication System in Routine AML Diagnostics (2016) (0)
Cytogenetic Aberrations In Splenic Marginal Zone Lymphoma (SMZL): A Study On 134 Cases (2010) (0)
Metabolic Fatty Liver Disease (2009) (0)
How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing (2022) (0)
Development of Molecular Mutations during the Evolution of Therapy-Related MDS and Therapy-Related AML (2014) (0)
MDS subclassification—do we still have to count blasts? (2022) (0)
Translocation t(8;9)(p12;q33) detected in cALL: A case report (2012) (0)
Mild hyperphenylalaninemia (2020) (0)
LeukemiaNet: A transnational model for cooperative leukemia research. (2011) (0)
Abstract LB-329: Enhancing the resolution and accelerating the pace of translational fusion characterization in oncology by RNA sequencing (2016) (0)
Significance of Flow Cytometric and Mutational Findings in Patients with Cytopenias and Limited or No Signs of Myelodysplasia By Cytomorphology (2015) (0)
Assessment of age as its own risk factor in AML. (2012) (0)
Analysis of Philadelphia Negative Clones Detected during Treatment with Tyrosine Kinase Inhibitors: A Study on 63 CML Cases. (2007) (0)
Abstract 4259: Defining subtle cancer subtypes using the darkest DNA (2019) (0)
Detection of Dysplastic Features by Multiparameter Flow Cytometry in Myelodysplastic Syndromes in Relation to Cytomorphology and Cytogenetics. (2007) (0)
Assessment of CD30 expression on mast cells in systemic mastocytosis by immunohistochemistry versus multiparameter flow cytometry and correlation to clinical parameters (2016) (0)
Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype. (2021) (0)
Significance Assessment of Mutations in MDS Patients Using Publicly Available Databases: A Study with 944 Samples and 6 Most Significantly Mutated Genes (2015) (0)
Analysis of BRCA1 and BRCA2 Mutations and Gene Expression in Hematological Malignancies - Implications for Differential Involvement in Pathogenesis of Lymphoid Neoplasms (2018) (0)
Comprehensive Analysis of Mixed Phenotype Acute Leukemia (MPAL) By Whole Genome Sequencing (2017) (0)
Using Whole Genome Sequencing (WGS) of 3256 Patients with Hematologic Malignancies to Determine Genome Instability (2018) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION (2023) (0)
Epigenetic Enzyme Mutations in Myeloid Malignancies Are Selected By Chromatin-Remodeling Requirements That Vary By Lineage- and Maturation-Stage (2021) (0)
The Recently Suggested MDS/MPN Subgroup “Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis (RARS-T)” Demonstrates Unique Clinical, Cytogenetic, and Molecular Aspects: A Comprehensive Analysis of 57 Cases Strictly Defined According to WHO Criteria (2010) (0)
Molecular Characterization of B-Cell Neoplasms Harboring MYC Translocations (2013) (0)
Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup? (2022) (0)
Whole Genome Sequencing in Routine Hematologic Samples: How to Proceed Analyses Best When Germline Controls Are Missing? (2018) (0)
Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria (2020) (0)
Abstract 2707: Targeted RNA sequencing reveals thus far unknown diagnostically relevant fusion partners confirming its diagnostic potential (2017) (0)
Comprehensive Biologic Characterization of 99 Multiple Myeloma Patients Using Cytomorphology, FISH, Gene Expression Profiling and Mutation Screening Leads to Important Clinical and Therapeutic Insights (2016) (0)
Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression (2022) (0)
CLL-156: Novel CCL22 Mutations Drive Chronic Lymphoproliferative Disorder of NK Cells Through Biased GPCR Signaling (2021) (0)
Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation (2022) (0)
Co-Occurrence of Separate BCR-ABL1-Positve and JAK2V617F-Positive Clones in 23 Patients Reveals Biologic and Clinical Importance (2014) (0)
CML Patients with Philadelphia-Negative Clones Occurring During Treatment with Tyrosine Kinase Inhibitors Harbor Molecular Mutations Typical for MDS. (2012) (0)
Comprehensive Cytogenetic and Molecular Genetic Characterization of T-PLL Identifies for the First Time BCOR Mutations in a Lymphatic Disease. (2012) (0)
CBL Mutations Are Correlated with CMML, Frequently Associated with RUNX1 but Mutually Exclusive of JAK2V617F Mutations. (2009) (0)
About 17% of AML with NPM1 mutations Show a Specific Pattern of Chromosome Aberrations but These Cases Do Not Differ Prognostically from AML with NPM1 Mutations Carrying a Normal Karyotype (2008) (0)
A MAFB Associated Regulatory Network Distinguishes CMML from Other MDS/MPN Overlap Entities (2018) (0)
Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy (2022) (0)
TP53 Mutations in Acute Myeloid Leukemia (2015) (0)
Specific Molecular Mutations with Prognostic Relevance in AML with Normal Karyotype Are Also Associated with Outcome in AML with Aberrant Karyotype: A Study on 1981 Cases, (2011) (0)
Impact of unbalanced karyotypes at diagnosis on prognosis of CML. (2015) (0)
DNA Methylation and Genetic Profiles in 320 Patients with Myelodysplastic Syndromes (2018) (0)
Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards (2016) (0)
Abstract 4602: Recurrent pathway mutations of multiple components of cohesin complex in myeloid neoplasms. (2013) (0)
Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularely Defined Unique Entity (2011) (0)
Atlas of Genetics and Cytogenetics in Oncology and Haematology (2010) (0)
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations (2023) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling (2021) (0)
Frequency and Prognostic Impact of CD8 Expression In 5,523 Patients with Chronic Lymphocytic Leukemia (CLL) In Relation to Chromosomal Aberrations, IGHV Mutational Status and ZAP-70 Expression. (2010) (0)
Comprehensive Molecular Analyses of BCR-ABL1 Negative MPN Show That PMF Is Genetically Much More Heterogeneous Than ET and PV (2014) (0)
Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups (2012) (0)
Molecular Analysis of Myelodysplastic Syndrome with Isolated Del(5q) Reveals a Broad Spectrum of Clinically Relevant Mutations: A Study on 119 Patients and 26 Genes (2014) (0)
Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment (2022) (0)
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies. (2023) (0)
High BAALC Expression in Cytogenetically Normal Acute Myeloid Leukemia Strongly Correlates with Adverse Markers Such As RUNX1 mut, MLL -PTD and FLT3 -ITD and Is Useful for Disease Monitoring (2012) (0)
Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications (2019) (0)
Acute Lymphoblastic Leukemia (ALL) with Low-Hypodiploid/near Triploid Karyotype Is a Specific Clinical Entity with Poor Outcome (2012) (0)
The Evolution of Genetic Aberrations in CML Patients Harboring a Ph-Negative Clone: A 6-Year Follow-up Study of 52 Patients (2018) (0)
Chronic Myeloproliferative Disorders (2012) (0)
Correction: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing (2022) (0)
BAALC Expression Is a Feasible Marker for Risk Stratification and Detection of Minimal Residual Disease in Cytogenetically Normal Acute Myeloid Leukemia (2015) (0)
High-Throughput Sequencing to Identify Cytogenetic and Molecular Genetic Aberrations in 24 AML Exomes (2014) (0)
t(3;7)(q26;q21) as a secondary abnormality in MDS RAEB-2 (2011) (0)
Correction: complex landscape of alternative splicing in myeloid neoplasms (2021) (0)
RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression (2022) (0)
FISH in der Diagnostik hämatologischer Neoplasien (2008) (0)
Cytogenetic and Molecular Genetic Shifts in 27 Genes Investigated By NGS Depict Specific Routes from MDS to s-AML in 38 Patients with Paired Samples (2014) (0)
Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients (2021) (0)
DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity (2018) (0)
Deletion of the Tumor Suppressor Gene NF1 Is An Alternative Mechanism for Aberrant Activation of the RAS Pathway and Is Found in 11% of Acute Myeloid Leukemia. (2009) (0)
MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin-CD34+CD38- Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS (2013) (0)
Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease (2019) (0)
Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA (2015) (0)
PPM1D Mutations in MDS Patients with Deletion of Chromosome 5q (2017) (0)
Analysis of the IDH1G105 (SNPrs11554137) Polymorphism in 961 AML Patients and in a Large Cohort of 475 Healthy Controls (2011) (0)
the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes (2016) (0)
Specific T Cell Receptor Gene Repertoire Profiles in Subgroups of CLL Patients with Distinct Genomic Aberrations (2021) (0)
Correlation of Multiparameter Flow Cytometry and Fluorescence In Situ Hybridization in Quantifying Malignant Cells at Low Frequencies in B-Cell Lymphoproliferative Diseases. (2007) (0)
AML classification in the year 2023: How to avoid a Babylonian confusion of languages. (2023) (0)
High Frequency of AML1/RUNX1 Mutations in Specific Cytogenetic Subgroups in De Novo Acute Myeloid Leukemia. (2007) (0)
Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools (2022) (0)
Mutations In SETBP1 Occur In 3.1% Of De Novo AML and Show a Distinct Genetic Pattern That Highly Resembles Atypical CML (2013) (0)
Correlation Between Cytogenetic Aberrations Detected by Conventional Chromosome Banding Analysis and Specific Immunophenotypes in Patients with B-Cell Lymphoproliferative Diseases (2008) (0)
Incidential Findings of Mutations in the PIGA Gene Are Highly Specific for the Presence of PNH Clones (2021) (0)
14q Deletions Are Recurrent Aberrations in CLL and Other Mature B-Cell Neoplasms and Show a High Coincidence with An Unmutated IgVH Status and Trisomy 12, and Are Associated with An Intermediate Overall Survival and a Shorter Time to Treatment. (2009) (0)
Occurrence of T-Lymphocytes with Aberrant Immunophenotypes Suggestive of Mature T-Cell Neoplasms In Patients with Hairy Cell Leukemia (2010) (0)
Clinical characteristics and treatment with ruxolitinib in patients with PCM1-JAK2 and BCR-JAK2 positive myeloid/lymphoid neoplasms with eosinophilia (2017) (0)
Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study (2010) (0)
WT1 Expression as Follow up Marker in CML: Low Impact and Sensitivity Compared to BCR-ABL Specific RQ-PCR but High Impact for Detection of New Aberrant Clones in BCR-ABL Negative Follow up Samples (2008) (0)
Prognosis In Patients with MDS or AML and Bone Marrow Blasts Between 10% and 30% Is Not Associated with Blast Count but Depends on Cytogenetic and Molecular Genetic Parameters (2010) (0)
Screening for Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients with Cytopenia and Suspected Myelodysplasia Using the Fluorochrome-Conjugated Derivative of Aerolysin, FLAER (2008) (0)
Copy-Neutral Loss-of-Heterozygosity Adds Diagnostic and Prognostic Information to the Molecular Profiling of Hematological Malignancies (2021) (0)
High Incidence of RAS Signalling Pathway Mutations in MLL–rearranged Acute Myeloid Leukemia (2012) (0)
Methylation of the Proximal, Distal and Core Promoter of CEBPA in 574 Cases with Normal Karyotype AML and 44 with t(8;21) Disclosed Different Frequencies but No Impact on Prognosis (2011) (0)
Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes (2022) (0)
In Myelodysplastic/Myeloproliferative Neoplasms Aberrant Antigen Expression As Assessed by Multiparameter Flow Cytometry Is Related to Molecular Genetic Mutations (2011) (0)
Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns (2015) (0)
Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms (2016) (0)
Complex Aberrant Karyotypes Are Associated with Dismal Prognosis in CLL: Chromosome Banding Analysis Provides Important Prognostic Information in CLL in Addition to Interphase-FISH (2008) (0)
Automated Disease Classification Using Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data with Transparent Artificial Intelligence (AI) (2021) (0)
Deep-Sequencing Of The Molecular Landscape In Burkitt Lymphoma/Leukemia (2013) (0)
S886 CLASSIFICATION OF MYELOPROLIFERATIVE NEOPLASMS BASED ON DEEP LEARNING ALGORITHMS AND MOLECULAR GENETIC MARKERS SUPPORT DISTINCTION OF CML, PV, ET, AND PMF (2019) (0)
Next Generation Sequencing-Based Molecular Dissection Of Lineage-Specific Mutational Hierarchies In Oligoclonal Primary and Xenografted Myelodysplasia (2013) (0)
Targeting Genomic Heterogeneity of Adult Acute Lymphoblastic Leukemia (2014) (0)
Genetic Profiling of Adult Acute Lymphoblastic Leukemia Cells by Single Nucleotide Polymorphism Oligonucleotide Microarray. (2007) (0)
Effect of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV. (2011) (0)
Deficiency of RPS14 Beyond the Haploinsufficient Loss in Del(5q) (2021) (0)
Analysis of 12 Genes in 268 Cases with CMML Identifies ASXL1 Mutations As the Most Important Genetic Alteration Associated with Adverse Outcome (2012) (0)
Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions. (2022) (0)
In BCR-ABL1 Negative Myeloproliferative Neoplasms the Detection of JAK2exon12, MPLW515, CBL, KITD816V, FIP1L1-PDGFRA Mutations Are Closely Linked to Specific Entities, Whereas the JAK2V617F, TET2, or EZH2 Mutations Demonstrate a Broader Diversity: Patterns From Diagnostic Reports of 18,547 Patients (2010) (0)
Flow Cytometric Assessment of Myeloid Nuclear Differentiation Antigen (MNDA) Expression in Myelodysplastic Syndromes As a Diagnostic Marker (2011) (0)
Mutant TP53 prevents Telomere Shortening in Acute Myeloid Leukemia (2021) (0)
Translocation t(14;19)(q32;q13) Is a Rare Abnormality in CLL and Associated with Trisomy 12, an Unmutated IgVH Status and a Distinct Gene Expression Profile. (2007) (0)
Risk Stratification In Chronic Lymphocytic Leukemia Patients With IGHV3-21 Gene Usage According To Presence Of Stereotypy and Mutations In SF3B1 (2013) (0)
INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2019) (0)
Time Points, Dynamics and Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with NPM1 mutation: A Study on 428 Patients (2016) (0)
EZH2 Mutations Can Be Detected in 23% of t(10;11)(p13;q14)/PICALM-MLLT10 Positive Acute Leukemias, (2011) (0)
156 a Novel Pcr-Based Assay for Targeted Quantification of Del(5q) in Myelodysplastic Syndromes (2015) (0)
A Study on Paired Tissue Sequencing in Hematologic Diseases to Distinguish Somatic from Germline Sequence Variants in Routine Diagnostics (2016) (0)
Impact of emerging ACA on survival in chronic myeloid leukemia (CML) (2022) (0)
Analysis of the Genetic Background in Patients with Myeloid Malignancies and Divergent Findings Regarding Blasts As Determined By Cytomorphology and Flow Cytometry (2019) (0)
Primary and Secondary Hematological Neoplasms - Are They Related? (2019) (0)
O-005 Mutations in U2AF1 highly associate with MDS-RAEB and del(20q) (2013) (0)
Clonal hierarchies and dynamic evolution in Myelodysplastic Syndromes (MDS) upon therapy (2016) (0)
Prognostic Impact of NOTCH1 Mutations in Chronic Lymphocytic Leukemia (CLL): A Study On 538 Patients. (2012) (0)
Therapy-Related Myeloid Neoplasms (tMN) Following Treatment of Acute Myeloid Leukemia (AML): Exome Sequencing Reveals the Presence of an Ancestral Clone Refractory to Chemotherapy (2018) (0)
Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course, (2011) (0)
Comprehensive Genetic Analyses Of 213 PMF Patients Revealed 13% Of SRSF2 Mutations Being Strongly Correlated To ASXL1 Mutations (2013) (0)
IKZF1 deletions Are Detected In 40.3% Of 270 Adult B-Precursor-ALL and Are Independently Associated With BCR-ABL1 Positivity and Inferior Outcome (2013) (0)
Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM (2022) (0)
Abnormalities Detected By Array CGH and Fluorescence in Situ Hybridization in AML with Normal Karyotype Lacking Mutations in NPM1, CEBPA, RUNX1 and MLL Partial Tandem Duplications Are Associated with Unfavorable Outcome (2015) (0)
Guidance for reporting the interpretation of cytogenomic test results in haematological neoplasms (2019) (0)
Preview : Published ahead of advance online publication WT 1 mutations are secondary events in AML , show varying frequencies and impact on prognosis between genetic subgroups (2014) (0)
Analysis For Loss Of 13q Heterozygosity Using STR Or SNP Analysis Can Replace Analysis Of FLT3-ITD To Detect Prognostically Adverse AML (2013) (0)
Short communication Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia (2007) (0)
Cracking a Nut with a Sledgehammer? - Broadening the Spectrum of Gene Mutation Analysis in MDS Does Not Add Clinically Relevant Information (2020) (0)
O-006 SF3B1 mutations in MDS subgroups and s-AML and their association with cytogenetics and other molecular markers (2013) (0)
IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup (2022) (0)
ERG Overexpression Is Highly Associated With ERG Gene Amplifications In Patients With Myeloid Malignancies (2013) (0)
Acknowledgement to Reviewers (2012) (0)
Mathematical Modeling and Comparisons of Relapse Patterns in AML with 11q23/ MLL translocations and Normal Karyotype AML with MLL -PTD (2011) (0)
S129 TP53 SOMATIC MUTATIONS AS PRE-LEUKEMIC EVENTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (2019) (0)
AML with RUNX1 Mutations and Loss of RUNX1 Wild-Type - a Distinct Subset? (2015) (0)
Investigation Of Seven Genes Commonly Deleted In 271 Adult ALL Patients: Association With Cytogenetics and Clinical Features (2013) (0)
Characterization of Del(14)(q24q32) in Mature B-Cell Neoplasms By Array-CGH, Cytogenetics and Molecular Mutations (2015) (0)
KRAS mutations Frequently Coexist with High-Risk MLL Fusions and Are Independent Adverse Prognostic Factors in MLL-Rearranged Acute Myeloid Leukemia (2020) (0)
Correlation of Cytomorphology, Immunophenotyping, and Interphase Fluorescence in Situ Hybridization (FISH) in 381 Patients with MGUS and 310 Patients with Multiple Myeloma. (2009) (0)
Response: NPM1-mutated AML is an entity irrespective of whether or not chromosomal aberrations are present (2009) (0)
Pattern of Chromosomal Aberrations and IgVH Mutation Status in Patients with Monoclonal B-Cell Lymphocytosis (MBL) (2008) (0)
ETV6 Rearrangements Are Recurrent Genetic Events In Myeloid Malignancies and In AML Are Associated with NPM1- and RUNX1-Mutations and An Intermediate Prognosis (2010) (0)
Identification and Characterization of Three Novel Cytogenetically Cryptic EVI1 Rearrangements Identified in 27 AML Patients All Predicting An Unfavorable Outcome (2011) (0)
Characterization of myelodysplastic syndromes and acute myeloid leukemia with isodicentric X chromosome (2009) (0)
Incidence and prognostic impact of cytogenetic aberrations in systemic mastocytosis (2016) (0)
6.7 Microarray-Analysen (2008) (0)
Targeted Next-Generation Sequencing Of 2,761 Genes Detects Copy Number States and Molecular Mutations In a Single Approach (2013) (0)
Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability (2013) (0)
Whole Genome Sequencing Identifies Non-KIT Mutations and Cytogenetic Aberrations in Systemic Mastocytosis but Has Limited Sensitivity for Detection of KIT D816V (2021) (0)
Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity? (2015) (0)
Degree of Aberrant Antigen Expression in Myelodysplastic Syndromes Correlates with the Number of Molecular Mutations (2015) (0)
P-053 Characterization of 305 patients with myelodysplastic syndromes and 20q-deletion: Cytomorphological features, and concomitant cytogenetic and molecular genetic alterations (2013) (0)
Complete or Partial Deletions of IKZF1 Occur In 28% of Blast Crisis CML and Are the Only Recurrent Submicroscopic Alteration Associated with Disease Progression: An Analysis of 43 Cases Using High-Resolution Genome-Wide Copy Number DNA Arrays and Molecular Assays (2010) (0)
Targeted RNA Sequencing Is Capable of Identifying Thus Far Unknown Partner Genes in Leukemias with Rare Translocations and Provides Important Clinical and Therapeutical Information (2016) (0)
Serial Assessment of Patients with Suspected Myelodysplastic Syndromes: Significance of Flow Cytometric Findings As Validated by Cytomorphology, Cytogenetics, and Molecular Genetics (2011) (0)
Ultra-Deep Sequencing Leads to Earlier and More Sensitive Detection of the TKI Resistance Mutation p.T315I in CML (2014) (0)
Multiple analyses affirm the independent adverse influence of ABL/BCR breakpoint spanning deletions on surival in chronic myeloid leukemia (2007) (0)
219 RELATION BETWEEN MOLECULAR MUTATIONS AND ABERRANTLY EXPRESSED ANTIGENS IN MYELODYSPLASTIC SYNDROMES (2015) (0)
Complete hematologic response to sunitinib in an eosinophilia-associated chronic myeloproliferative disorder with an ETV6-FLT3 fusion gene (2007) (0)
The diverse landscape of fusion transcripts in 25 different hematological entities (2020) (0)
5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap (2014) (0)
Case Report Section Paper co-edited with the European LeukemiaNet (2010) (0)
Analyzing the Transcriptome Discovers up-Regulation of HOXA Genes in Patients with Myeloid Neoplasms and Isochromosome 17q and Mutations in ASXL1, SETBP1 and SRSF2 (2016) (0)
Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes (2015) (0)
Coexistence of myelodysplastic syndromes and plasma cells disorders. a cytogenetic review (2010) (0)
Putative Germline Variants in the Predisposition Genes DDX41, ETV6 and GATA2 investigated in 1,228 Patients with Sporadic AML or MDS (2020) (0)
Homozygosity of Mutated Calreticulin in Myeloproliferative Neoplasms By an Acquired Chromosome 19p UPD Is Associated with Deletions in the Long Arm of Chromosome 5 and SF3B1 Mutations (2016) (0)
Impact of 1p Deletions in Myelodysplastic Syndromes and Secondary AML Arising from Myelodysplastic Syndromes (2016) (0)
Flow Cytometric Assessment of the T-Cell Receptor Vβ Repertoire Identifies Clonal T-Cell Populations with High Specificity and Sensitivity. (2012) (0)
The Prognostic Impact of High EVI1 expression In AML Is Due to Its Close Correlation to Rearrangements Involving EVI1 or MLL, which Are Cytogenetically Cryptic In a Subset of Patients : a Study on 332 Cases. (2010) (0)
Related Versus Unrelated Donor Transplantation for High Risk (HiRi) Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). (2007) (0)
Higher Percentages of Ring Sideroblasts and SF3B1 Mutations in Patients with AML Correlate with Mutations in TP53 and Adverse Cytogenetics, but Have No Independent Impact on Outcome (2015) (0)
Microarray Analysis Detects Unique Expression Pattern for NPM1-Mutated AML with Normal Karyotype and Reveals Pathobiological Insights. (2007) (0)
FOS Expression Distinguishes Two Groups of Atypical CML (aCML) Allowing Targeted Therapy (2018) (0)
Current and future activities in cytogenetics-a summary from WP 11 (0)
AML with Translocation T(8;16) Shows Unique Cytomorphological, Cytogenetic, Molecular, and Prognostic Features and Therefore Qualifies as An Own Entity According to WHO Criteria. (2008) (0)
To the editor: Elevated ﬁbrinogen (cid:1) (cid:2) ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome (2009) (0)
Association of Interphase Fluorescence in Situ Hybridization (IP-FISH) Response Criteria with Conventional Metaphase Cytogenetics in CML Patients On Therapy. (2009) (0)
RUNX1 Mutated AML Are Associated with a Distinct Pattern of Cytogenetic and Additional Molecular Genetic Abnormalities (2014) (0)
B-Cell Lymphoproliferative Disorders with t(11;14)(q13;q32) or t(14;18)(q32;q21) Can Be Subdivided into 4 Distinct Categories Based on Their Pattern of Additional Cytogenetic Aberrations and Antigen Expression. (2007) (0)
Short communication Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases (2007) (0)
myeloid leukemia the tyrosine kinase inhibitor resistance mutation T315I in chronic Ultra-deep sequencing leads to earlier and more sensitive detection (2016) (0)
Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing (2022) (0)
Coincidence of JAK2V617F and BCR-ABL Is a Very Rare Event: Identification of 4 among 2317 Cases with Suspected CMPD. (2007) (0)
Impact of Expression of BAALC , CDKN1B, ERG , EVI1 , and MN1 on Prognosis and Their Association with Karyotype, FLT3 -ITD, NPM1 and MLL -PTD Status In Adult AML: A Comprehensive Study on 286 Cases (2010) (0)
Impact of FLT3 Mutation Status and Other Genetic Parameters In Acute Promyelocytic Leukemia (APL) with t(15;17)(q22;q12)/PML-RARA. (2010) (0)
Role of Screening for Molecular Mutations in Patients with Suspected MDS (2017) (0)
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis (2022) (0)
Characterization of Three New Fusion Genes Generated by Disruption of PDGFRB in Eosinophilia-Associated Chronic Myeloproliferative Neoplasms (2008) (0)
Abstract 5788: Genomic and transcriptomic profiles of DNA damage response genes in acute myeloid leukemia (2022) (0)
Comprehensive Analysis of 22 Cases with Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals Mutations in DNA Repair Genes and Two Distinct Subgroups Defined By Differential Gene Expression with Prognostic Impact (2019) (0)
Clinical Relevance of Concomitant Gene Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia. (2012) (0)
Comprehensive Molecular Profiling of T-Cell Acute Lymphoblastic Leukemia Identifies Mutations in 76 (97.4%) of 78 Patients (2011) (0)
CASE REPORTS in HAEMATOLOGY (Paper co-edited with the European LeukemiaNet) (2010) (0)
Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype (2018) (0)
Ultra-Deep Next-Generation Sequencing (NGS) Detects BCR-ABL1 Kinase Domain Mutations with High Sensitivity and Allows to Monitor the Composition of Distinct Subclones During Tyrosine Kinase Inhibitor Treatment (2010) (0)
Towards a Comprehensive Prognostic Score in CLL Based On a Combination of Genetic Parameters. (2009) (0)
Complex 3q26/EVI1 Rearrangements Genocopy Inv(3)/t(3;3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression (2018) (0)
A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI (2022) (0)
Prognostic Impact of Multiparameter Flow Cytometry in Patients Analyzed for Suspected MDS. (2012) (0)
The Pattern Of Cytogenetic Aberrations In CML BC Stratified For Treatment (2013) (0)
Automated Comprehensive Diagnostics of Hematologic Neoplasms By Artificial Intelligence Models Using Flow Cytometric Raw Matrix Data (2021) (0)
Whole Genome Sequencing and RNA Sequencing of 27 Patients with Persistent Polyclonal B-Cell Lymphocytosis Reveals a High Mutation Frequency/Overexpression of Lymphoma Associated Genes: Really a Benign Disorder? (2018) (0)
Molecular Analysis of RAS-RAF Tyrosine-Kinase Signaling Pathway Alterations in Multiple Myeloma (2011) (0)
NPM1 Mutations Have a High Impact On the Development of Secondary AML. (2009) (0)
A Distinct Pattern of Additional Aberrations and Novel Mechanisms of MLLRearrangements Are Detectable in AML with 11q23 Aberrations Using SNP Arrays (2008) (0)
Short communication Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia (2010) (0)
PS922 BENEFITS OF RNA SEQUENCING IN DETECTING RECURRENT AND NOVEL FUSION TRANSCRIPTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (2019) (0)
The Detection of Multilineage Dysplasia (MLD) Has No Influence on Prognosis in NPM1 Mutated Acute Myeloid Leukemia (AML) with Normal Karyotype (2008) (0)
Molecular dissection of normal karyotype acute myeloid leukemia. (2020) (0)
Evaluation of BRAF V600E, NRAS and KRAS Mutations As Well As IGHV Usage for Diagnostic Use in Hairy Cell Leukemia, Hairy Cell Leukemia-Variant and Splenic Marginal Zone Lymphoma. (2012) (0)
Somatic TP53 mutations are pre-leukemic events in acute lymphoblastic leukemia. (2022) (0)
Unrelated clones in AML/MDS - characterisation and prognostic relevance (2010) (0)
t(1;21)(p32;q22) as a non-random abnormality in AML M4 (2011) (0)
Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes (2022) (0)
A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups (2022) (0)
MYC Translocations In Mature B-Cell Neoplasms: Single, Double, Triple and Quadruple Hit Lymphoma (2013) (0)
PS1133 GENOMIC ARRAYS IDENTIFY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA WITH GENOMIC COMPLEXITY: A MULTI-CENTER STUDY (2019) (0)
Abstract 3275: Comparison of somatic variant interpretation results between human experts and automated classification using AMP/ASCO/CAP guidelines (2018) (0)
Characterization and Prognostic Impact of Multiple Productive IGHV Rearrangements in CLL (2016) (0)
der(9;18)(p10;q10) (2011) (0)
Topic: AS01-Diagnosis/AS01a-Cytomorphology: AUTOMATED DIGITAL TOOL FOR MDS AND MDS/MPN CLASSIFICATION USING WHO AND ICC: INTERNATIONAL GUIDELINES WORKING GROUP ON MDS DIAGNOSIS, PROGNOSIS, AND GERMLINE PREDISPOSITION (2023) (0)
WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis (2013) (0)
An Approach to Virtual Karyotyping for Unbalanced Rearrangements Based on Gene Expression Data. (2007) (0)
Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity (2013) (0)
Development and validation of a real-time quantification assay to detect and monitor BRAF V 600 E mutations in hairy cell leukemia (2012) (0)
A Case of Myelodysplastic Syndrome with a Translocation t(1;12)(p36;p13) (2011) (0)
Array Based Comparative Genomic Hybridization Detects Copy Number Alterations in 80.3% of Adult Acute Lymphoblastic Leukemia (ALL) with Normal Karyotype or Failed Chromosome Banding Analysis and Identifies a Subset with Only Submicroscopic Alterations Associated with Favorable Outcome (2014) (0)
65 MYELODYSPLASTIC SYNDROMES ARE CHARACTERIZED BY RECURRENT PATTERNS IN PATIENT-INDIVIDUAL MUTATIONAL HIERARCHIES THAT ARE SUBJECT TO HIGHLY DYNAMIC SUBCLONAL EVOLUTION DURING THERAPY AND DISEASE PROGRESSION (2015) (0)
Comprehensive Analyses of Mantle Cell Lymphoma with a 17 Gene Panel Reveal an Accumulation of TP53 Mutations in SOX11 Negative Patients (2014) (0)
The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1). (2009) (0)
Identification of Recurrent Submicroscopic Deletions of chromosome1q31.3 As Possible Molecular Prognostic Markers in Acute Promyelocytic Leukemia (APL) (2011) (0)
Dreams can come true: the first steps toward a peripheral blood screening test for the early detection of tumors have been taken. (2019) (0)
Myelodysplastic Syndromes and Philadelphia Negative Chronic Myeloproliferative Diseases Show an Overlapping Pattern of Cytogenetic Aberrations. (2007) (0)
ALL-276: Complex Karyotype with ≥3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) (2020) (0)
P040 Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetic, and clinical data (2009) (0)
[Diagnostics in unclear cytopenia-How and when do we screen for clonal hematopoiesis?] (2022) (0)
Older-age AML: Disease biology and dose response (2007) (0)
Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022 (2022) (0)
Targeted Next-Generation Sequencing (NGS) Enables for the First Time the Detection of Point Mutations, Molecular Insertions and Deletions, as Well as Leukemia-Specific Fusion Genes in AML in a Single Procedure. (2009) (0)
Acute Monoblastic/Monocytic Leukemia and Chronic Myelomonocytic Leukemia Share Common Immunophenotypic Features but Differ in the Extend of Aberrantly Expressed Antigens and the Amount of Granulocytic Cells. (2009) (0)
Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL (2022) (0)
Molecular characterization of EZH 2-mutant patients with 2 myelodysplastic / myeloproliferative neoplasms 3 (2017) (0)
Genomic Mechanisms of 17p / TP53 Loss in Primary “ultra High-risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial (2014) (0)
NPM1 Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis (2018) (0)
A Completely Digital Workflow for Differentials in Bone Marrow Cytomorphology Supported By Machine Learning Provides Promising Results in Object Detection (2021) (0)
MMA (2020) (0)
The Type of Genetic Abnormalities Causing Loss of 5q Varies Between MDS and AML and Is Associated with Worse Prognosis in MDS (2012) (0)
The Landscape of RUNX1 Mutations in Acute Myeloid Leukemia: Investigations On Stability of Mutations At Relapse and Utility As a Marker for Minimal Residual Disease (2012) (0)
A NUP98-NSD1 Fusion Gene Can Be Detected in a Small Subset of Adult AML Patients with Normal Karyotype (2011) (0)
ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia (2021) (0)
Molecular Characterization of Acute Myeloid Leukemia (AML) Patients Who Relapse More Than 3 Years after Diagnosis: An Exome Sequencing Study of 31 Patients (2018) (0)
NPM1 Mutated AML Can Relapse with Wildtype NPM1 and Evolve with Novel Mutations: Implications for Pathobiology and MRD Monitoring (2017) (0)
Complexity of CEBPA Mutated Acute Myeloid Leukemia (2014) (0)
TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression. (2009) (0)
Long Intergenic Non-Coding RNAs Unambiguously Classify AML Subgroups (2018) (0)
Molecular determinants of prognosis in acute myeloid leukemia (AML) with normal karyotype (2009) (0)
Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDS (2019) (0)
The Use of NGS for Molecular Investigations in Leukemia Adds Important Biological, Clinical and Prognostic Information Due to Its Higher Sensitivity in Comparison to the Gold Standard Sanger Sequencing (2016) (0)
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]. (2007) (0)
Response to Imatinib Mesylate In CML Patients as Assessed by Quantitative Real Time PCR Can Predict the Probability for Resistance Mutations In the BCR-ABL1 Kinase Domain. (2010) (0)
Identification and Characterization of Potential Candidates for Treatment Targeting Apoptosis Pathways in Patients with Hematological Neoplasms (2018) (0)
Development of a DNA-Based Targeted Assay Suitable for Accurate Quantification of Chromosomal Deletions in Myelodysplastic Syndromes with Deletion (5q) and Other Clonal Diseases (2014) (0)
Analysis of Genetic Variants and Expression Levels of Human Organic Cation Transporter 1 (HOCT1) and Genetic Variants in MDR1 in CML: Weak Associations Were Detected but a Major Role in Clinical Response to Imatinib Resistance Is Unlikely (2008) (0)
Comprehensive Investigation of 225 Patients with Myeloid Malignancies and Erythroid Hyperplasia (≥50%) Demonstrates That Acute Erythroid Leukemia (AEL, according WHO Classification 2008) Differs Significantly From MDS but Overlaps with Other AML Subtypes and Pure AEL Regarding Clinical and Genetic F (2010) (0)
Characterization of CMML with Normal Karyotype in Comparison to CMML with Aberrant Karyotype (2015) (0)
Landscape of Secondary Genetic Lesions in Acute Myeloid Leukemia with Inv(16)/CBFB-MYH11 (2015) (0)
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Claudia Haferlach?

Claudia Haferlach is affiliated with the following schools:

Ludwig Maximilian University of Munich
University of Pavia

Claudia Haferlach's Academic­Influence.com Rankings

Why Is Claudia Haferlach Influential?

Claudia Haferlach's Published Works

Published Works

What Schools Are Affiliated With Claudia Haferlach?

Claudia Haferlach's AcademicInfluence.com Rankings